NIDA’s Current Portfolio and Research Interests
Sarah Q. Duffy, Ph.D., Associate Director for Economics Research, Division of Epidemiology, Services, and Prevention Research duffys@nida.nih.gov 

About 40 grants in DESPR, Division of Clinical Neuroscience and Behavioral Neuroscience Research, Clinical Trials Network
Economic evaluations (CEA/CBA/CUA)
(
/
/
)
 Stand alone grant
 Aim in an efficacy or effectiveness grant



Cost of drug use, addiction (COI studies) C t f t t
Costs of treatment, prevention services and t ti i d systems
Demand for drugs
df d

Effects of government policies on drug users and on the addiction treatment system

Effects of treatment and prevention on p
economic outcomes 
Private insurance coverage of addiction P
i t i
f ddi ti treatment

Methods studies

Olmstead (R21 DA02859)
 Estimate the price elasticity of demand for drugs by E i
h i l i i f d
d f d
b treatment status among heroin users
 Collect data via an interactive voice response system that calls subjects to collect info on types and amounts of drugs purchased, price and quality
 Subjects will also participate in hypothetical drug j
p
p
yp
g
purchasing experiments
 Results will be compared 
Hill and Rosenman (R21 DA025139)
 Develops and tests techniques for addressing D l d t t t h i
f dd
i multiple sources of estimation bias in studies evaluating outcomes of real‐world, community‐
l ti t
f l
ld it
based prevention programs
 Applies the methods to a specific prevention program

Effects of health reform, parity on services
 Medicaid expansions
 Inclusion of SA Tx among essential benefits
 Medical homes, etc.
M di l h
t

Enabling health reform, parity  Performance and quality measurement & management
 Casemix‐adjustment
j
 Outcomes measures

Costs efficiency
Costs, efficiency

Economics of Treatment and Prevention Services for Drug & Alcohol Abuse PA‐08‐172 (R03),‐173 (R21), ‐174 (R01)

Health Services Research on the Prevention and Treatment of Drug & Alcohol Abuse PA‐08‐263 (R01), ‐264 (R21), ‐265 (R03)

Accelerating the Pace of Drug Abuse Research Using g
g
g
Existing Epidemiology, Prevention, and Treatment Research Data (R01) PAR‐10‐018

Mechanism for Time‐Sensitive Drug Abuse Research (R01) PAR 10‐072

Seek, Test, Treat and Retain: Addressing HIV among Vulnerable Populations (RFA DA 11
among Vulnerable Populations (RFA‐DA‐11‐
001) (NIDA and NIMH)
 Does increasing HIV testing and reducing viral load among HIV+ individuals reduce transmission rates?
 How can this be done?
 Economic Evaluation
 $8,500,000; due 11/15/2010
$8 500 000; due 11/15/2010



From concept stage through revision
One on one One‐on‐one Team approach (multiple PO’s or whole branch)
 Conference call  Adobe Connect 
Concept paper template http://www nida nih gov/about/organization/de
http://www.nida.nih.gov/about/organization/de
spr/HSR/HSRindex.html

Grant Purpose
Mechanism (R01/R03/R43 etc), amount and duration G
P
of funding

Problem & Significance Why this topic needs study, the payoff to Wh this topic needs st d the pa off to science AND public health, why the project is unique and innovative.

Question Specific hypotheses, as well as theories and model(s) that Specific hypotheses as well as theories and model(s) that guide them 
Design & Analysis
g
y Population , interventions, controls, measures, p
,
,
,
,
required sample and power, statistical approach

Team & Logistics How your career stage, expertise, and experience qualify you to lead a project of the size, scope, & technology proposed; lif t l d j t f th i & t h l
d key collaborators; organizations whose cooperation you will need to access subjects/data/equipment/field sites
Thank You!
www.drugabuse.gov
© 2010 Lori Ducharme